Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers

Table 3 Plasma levels of tested parameters and CA 125 and SCC-Ag in patients with cervical cancer, dysplasia patients and in control group (median and range)

		M-CSF (pg/mL)	VEGF (pg/mL)	CA 125 (U/mL)	SCC-Ag (ng/mL)
Cervical cancer	Squamous cell carcinoma	510.55^a/b/e 102.15–2513.75	140.20^a/b/c/e 11.80–577.22	17.99^a/e 4.40–120.10	1.20 ^a/b/c/e 0.50–14.10
	Adenocarcinoma	442.41^a/b 95.23–1696.65	158.88^a/b/e 56.76–615.50	15.50 6.34–77.41	1.30^a 0.70–7.10
	Total	500.55 ^a/e 95.23–2513.75	142.00 ^a/e 11.80–615.50	17.60 ^a/e 4.40–120.10	1.20 ^a/e 0.50–14.10
CIN grade	CIN I	132.40 11.80–615.50	47.40 28.20–407.22	132.40 11.80–615.50	0.74 0.58–0.87
	CIN II	136.90 28.92–395.60	48.94 16.90–467.10	136.90 28.92–395.60	0.70 0.55–1.00
	CIN III	199.00 44.50–598.50	111.50 27.12–426.86	199.00 44.50–598.50	0.85 0.65–1.40
	Total	312.34 ^a 126.20–1830.20	62.60 16.90–467.10	14.90 2.53–78.30	0.80 0.30–5.20
Control group		251.50 ^d/e 119.63–935.29	45.80 ^d 11.20–194.50	11.70 3.50–366.00	0.75 0.40–1.60

CA 125: cancer antigen 125; SCC-Ag: squamous cell carcinoma antigen; M-CSF: macrophage-colony stimulating factor; VEGF: vascular endothelial growth factor
^aStatistically significant when compared with controls
^bStatistically significant when compared with patients with CIN I
^cStatistically significant when compared with patients with CIN II
^dStatistically significant when compared with patients with CIN III
^eStatistically significant when compared with patients with total CIN group

ISSN: 1471-2407